ValiRx Stock Price, News & Analysis (LON:VAL)

GBX 3.38 -0.12 (-3.43 %)
(As of 02/22/2018 04:00 PM ET)
Previous CloseGBX 3.38
Today's RangeGBX 3.25 - GBX 3.59
52-Week RangeGBX 0.90 - GBX 7.75
Volume1.54 million shs
Average Volume5.54 million shs
Market Capitalization£6.22 million
P/E Ratio-56.25
Dividend YieldN/A
BetaN/A

About ValiRx (LON:VAL)

ValiRx logoValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:VAL
CUSIPN/A
Phone+44-20-30084416

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-56.25
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.06)
Net IncomeN/A
Net MarginsN/A
Return on Equity-184.06%
Return on Assets-82.91%

Miscellaneous

EmployeesN/A
Outstanding Shares203,960,000

ValiRx (LON:VAL) Frequently Asked Questions

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

Where is ValiRx's stock going? Where will ValiRx's stock price be in 2018?

1 Wall Street analysts have issued twelve-month price targets for ValiRx's shares. Their forecasts range from GBX 6.50 to GBX 6.50. On average, they expect ValiRx's stock price to reach GBX 6.50 in the next year. View Analyst Ratings for ValiRx.

Who are some of ValiRx's key competitors?

Who are ValiRx's key executives?

ValiRx's management team includes the folowing people:

  • Satu Vainikka, Chief Executive Officer, Director
  • Gerald Desler, Chief Financial Officer, Director
  • George Morris, Chief Operating Officer, Director
  • Kevin John Alexander, Secretary, Non-Executive Director
  • Oliver de Giorgio-Miller, Non-Executive Chairman of the Board (Age 61)
  • Seppo Olavi Makinen, Non-Executive Director (Age 64)

How do I buy ValiRx stock?

Shares of ValiRx and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx's stock price today?

One share of ValiRx stock can currently be purchased for approximately GBX 3.38.

How big of a company is ValiRx?

ValiRx has a market capitalization of £6.22 million.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.


MarketBeat Community Rating for ValiRx (VAL)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ValiRx (LON:VAL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 6.50GBX 6.50GBX 6.50GBX 6.50

ValiRx (LON:VAL) Consensus Price Target History

Price Target History for ValiRx (LON:VAL)

ValiRx (LON:VAL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/12/2018Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
12/8/2016Northland SecuritiesReiterated RatingCorporateView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for ValiRx (LON:VAL)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

ValiRx (LON:VAL) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ValiRx (LON:VAL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ValiRx (LON VAL)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

ValiRx (LON VAL) News Headlines

Source:
DateHeadline
Global Endometriosis IndustryGlobal Endometriosis Industry
www.bizjournals.com - February 20 at 4:11 PM
ValiRxs VAL401 Shown To Have "Measurable" Improvement For PatientsValiRx's VAL401 Shown To Have "Measurable" Improvement For Patients
www.morningstar.co.uk - January 17 at 10:24 AM
ValiRxs (VAL) "Speculative Buy" Rating Reiterated at Beaufort SecuritiesValiRx's (VAL) "Speculative Buy" Rating Reiterated at Beaufort Securities
www.americanbankingnews.com - January 14 at 6:34 PM
US Patent Notice of Allowance for Compound VAL201US Patent Notice of Allowance for Compound VAL201
www.lse.co.uk - January 11 at 10:54 AM
ValiRx Allowed US Patent For VAL201 Therapeutic CompoundValiRx Allowed US Patent For VAL201 Therapeutic Compound
www.morningstar.co.uk - January 11 at 10:54 AM
YA II CD Builds 7% Stake In Biotechnology Firm ValiRx (ALLISS)YA II CD Builds 7% Stake In Biotechnology Firm ValiRx (ALLISS)
www.morningstar.co.uk - January 4 at 4:26 PM
With A 16.4% Earnings Drop Lately, Did ValiRx plc (LON:VAL) Underperform Its Industry?With A 16.4% Earnings Drop Lately, Did ValiRx plc (LON:VAL) Underperform Its Industry?
finance.yahoo.com - December 28 at 3:23 PM
ValiRx Converts USD520,000 Remaining Convertible Debt Into Shares (ALLISS)ValiRx Converts USD520,000 Remaining Convertible Debt Into Shares (ALLISS)
www.morningstar.co.uk - December 28 at 12:18 AM
VAL. The RNS statedVAL. The RNS stated
www.lse.co.uk - December 25 at 10:48 PM
ValiRx (VAL) Given "Speculative Buy" Rating at Beaufort SecuritiesValiRx (VAL) Given "Speculative Buy" Rating at Beaufort Securities
www.americanbankingnews.com - December 24 at 5:02 PM
UPDATE: ValiRx Nets GBP70,000 Through Warrant Exercises (ALLISS)UPDATE: ValiRx Nets GBP70,000 Through Warrant Exercises (ALLISS)
www.morningstar.co.uk - December 21 at 4:29 PM
ValiRx Shares Leap With Positive Results From VAL401 Phase Two TrialValiRx Shares Leap With Positive Results From VAL401 Phase Two Trial
www.morningstar.co.uk - December 12 at 10:57 AM
ValiRx Plc (VAL) Earns Speculative Buy Rating from Beaufort SecuritiesValiRx Plc (VAL) Earns Speculative Buy Rating from Beaufort Securities
www.americanbankingnews.com - November 19 at 6:16 AM
ValiRx Plc (VAL) Receives "Speculative Buy" Rating from Beaufort SecuritiesValiRx Plc (VAL) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - October 14 at 3:22 PM
How Does Investing In ValiRx plc (AIM:VAL) Impact Your Portfolio?How Does Investing In ValiRx plc (AIM:VAL) Impact Your Portfolio?
finance.yahoo.com - October 3 at 2:27 PM
ValiRx Details First Data From Phase II VAL401 Clinical TrialValiRx Details First Data From Phase II VAL401 Clinical Trial
www.morningstar.co.uk - September 28 at 8:54 AM
ValiRx Confirms VAL201 Clinical Trial For Cancer Patients Is "Ongoing" - London South East (registration) (blog)ValiRx Confirms VAL201 Clinical Trial For Cancer Patients Is "Ongoing" - London South East (registration) (blog)
www.lse.co.uk - September 20 at 10:50 AM
ValiRx Sees Good Progress In GeneICE Technology DevelopmentValiRx Sees Good Progress In GeneICE Technology Development
www.morningstar.co.uk - September 7 at 10:46 AM
ValiRX Draws Down USD400,000 From Convertible Loan FacilityValiRX Draws Down USD400,000 From Convertible Loan Facility
www.morningstar.co.uk - August 12 at 1:48 AM
ValiRX Draws Down USD400,000 From Convertible Loan Facility - London South East (registration) (blog)ValiRX Draws Down USD400,000 From Convertible Loan Facility - London South East (registration) (blog)
www.lse.co.uk - August 11 at 3:43 PM
ValiRx Says YA Global Master Converts USD250,000 Of Loan Notes (ALLISS) - London South East (registration) (blog)ValiRx Says YA Global Master Converts USD250,000 Of Loan Notes (ALLISS) - London South East (registration) (blog)
www.lse.co.uk - August 4 at 9:38 AM
ValiRX Signs Licensing Deal With Bangladeshs Mystic PharmaceuticalsValiRX Signs Licensing Deal With Bangladesh's Mystic Pharmaceuticals
www.morningstar.co.uk - July 29 at 8:20 AM
ValiRx Advisory Board Formed Of Existing, Former And New IndividualsValiRx Advisory Board Formed Of Existing, Former And New Individuals
www.morningstar.co.uk - June 23 at 12:32 AM
ValiRx Completes VAL401 Lung Cancer Study RecruitmentValiRx Completes VAL401 Lung Cancer Study Recruitment
www.morningstar.co.uk - June 15 at 3:17 PM
Company Overview of Azure Holdings plcCompany Overview of Azure Holdings plc
www.bloomberg.com - March 28 at 9:09 PM
VAL. With Val 401 d-VAL. With Val 401 d-
www.lse.co.uk - March 9 at 4:08 AM
ValiRx Says "Significant" Progression Made With VAL401 TrialValiRx Says "Significant" Progression Made With VAL401 Trial
www.morningstar.co.uk - March 9 at 4:08 AM
ValiRx Shares Drop On Discounted Placing To Progress Trial Development (ALLISS)ValiRx Shares Drop On Discounted Placing To Progress Trial Development (ALLISS)
www.morningstar.co.uk - March 3 at 5:11 AM
ValiRx Takes More Funds From Loan Facility To Progress TrialsValiRx Takes More Funds From Loan Facility To Progress Trials
www.morningstar.co.uk - December 3 at 9:37 AM
ValiRx Makes Progress With Second Clinical Testing Site For VAL401ValiRx Makes Progress With Second Clinical Testing Site For VAL401
www.morningstar.co.uk - December 2 at 10:28 AM

SEC Filings

ValiRx (LON:VAL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

ValiRx (LON VAL) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.